Most investors know the phrase "buy low, sell high." It's a fine piece of investing wisdom, but it isn't as straightforward as it seems. Even a company whose shares are performing well can be attractive if there's plenty of upside, especially for those willing to stay in the game for a long time: Buy high, sell higher.

Let's look at one corporation that has performed extremely well this year, but still looks like an excellent pick to hold onto over the next decade: Sarepta Therapeutics (NASDAQ: SRPT). The biotech's shares are up by 62% year to date, but they haven't peaked yet.

Sarepta Therapeutics' most important marketed product so far, Elevidys, which it developed in collaboration with Roche, was approved in June of last year. What makes it the most important? Like all of the company's other drugs, it treats Duchenne muscular dystrophy (DMD), a rare, progressive neuromuscular disease. Unlike Sarepta Therapeutics' other products, Elevidys targets the underlying causes of DMD, the first approved gene therapy to do so. Eligible patients are likely to prefer this option.

Continue reading

Source Fool.com